Project focused on ovarian cancer and family care in Shanghai
Official title: Shanghai Ovarian Cancer and Family Care Project
Run by Shanghai First Maternity and Infant Hospital · NCT06118307 · Data updated 2026-11-12
This study is trying to learn more about ovarian cancer by looking at patients, those at high risk, and healthy people in Shanghai to improve detection, treatment, and outcomes for everyone affected.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 3546 (estimated) |
| Sponsor | Shanghai First Maternity and Infant Hospital Academic / other |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Status | Recruiting |
| Started | January 1, 2013 |
| Main results expected | October 13, 2028 |
| Study ends | October 13, 2028 |
| Registry record updated | November 7, 2023 |
| Trial ID | NCT06118307 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients attending the oncology department for differential diagnosis of ovarian cancer, those with known high-risk factors, and individuals with normal findings from physical examinations.
✕Probably not a fit
Patients with evidence of another active cancer or those who have undergone prior bilateral oophorectomy may not benefit from this project.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The Shanghai Ovarian Cancer and Family Care Project aims to investigate ovarian cancer through a comprehensive approach that includes multiple cohorts: patients diagnosed with ovarian cancer, those at high risk, and healthy individuals. This observational project leverages hospital-based resources to enhance understanding of ovarian cancer detection, prevention, early diagnosis, treatment, and prognosis. By analyzing data from these diverse cohorts, the project seeks to address critical gaps in ovarian cancer research and improve patient outcomes.
Why it matters
Potential benefit: If successful, this project could lead to improved strategies for the early detection and prevention of ovarian cancer, ultimately enhancing patient survival rates.
How similar studies have gone: Other studies focusing on ovarian cancer cohorts have shown promise in improving understanding and outcomes, indicating that this approach is supported by previous research.
Who can join: the full rules
Show full inclusion / exclusion criteria
Participant meet the criteria for one of the following conditions: * Patients attending the oncology department require differential diagnosis of ovarian cancer. * Patients with known high-risk factors for ovarian cancer, such as history of ovarian cancer or BRCA-associated cancer, etc. * Patients attending the Physical Examination Center who have normal findings on physical examination and no symptoms. Exclusion Criteria: * Individuals with evidence of another active cancer. * Individuals who have prior bilateral oophorectomy. * Individuals who are unwilling or unable to sign the informed consent form.
Where it's running
-
Shanghai first maternity and infant hospital
Shanghai, Shanghai Municipality, China Recruiting
Study contacts
- Study coordinator: Yu Wang, MD; PhD
- Email: renjiwangyu@126.com
- Phone: 20261208
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
CR-002 study in adults with advanced solid tumors
This trial tests CR-002 as a single therapy to see if it is safe and tolerable in adults with locally advanced or metastatic solid tumors
-
VT-101 in Advanced Ovarian Cancer: early safety study in adults
This early-phase trial tests VT-101 in adult women with advanced, recurrent, or relapsed epithelial ovarian cancer to see if it is safe, how the body handles it, and whether there are any initial signs of activity.
-
Methylation markers in self-samples to help detect gynecological cancers
This study tests whether self-collected urine and vaginal samples can reveal DNA methylation or other genetic markers that indicate endometrial, ovarian, vulvar, or vaginal cancers in women who are at risk or have postmenopausal bleeding.
-
Radiotherapy for gynecologic cancer with up to 10 metastatic sites
This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.
-
EHR-based approach to boost HBOC genetic testing in at-risk women
A new EHR tool-based program tests whether computer prompts and real patient resources can help more women with family histories of breast or ovarian cancer get HBOC genetic testing.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.